Frankfurt - Delayed Quote EUR

Kodiak Sciences Inc. (K27.F)

3.2600

+0.0160

+(0.49%)

As of 8:08:25 AM GMT+2. Market Open.

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah.

PR Newswire 5 days ago

KOD
April 2025's Promising Penny Stocks

Over the last 7 days, the market has remained flat, but it is up 5.7% over the past year, with earnings forecast to grow by 13% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still present significant opportunities when backed by solid financials. We've selected three examples of penny stocks that combine balance sheet strength with potential for outsized gains, offering investors a chance to uncover hidden value in...

Simply Wall St. 18 days ago

DSGN

QD

KOD
Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)

Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks last month

KOD
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks last month

KOD
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire last month

KOD
Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5?

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Kodiak Sciences Inc. (NASDAQ:KOD) stands against other hot biotech stocks under $5. The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention. After a […]

Insider Monkey last month

KOD
KOD Completes Enrollment in Phase III Study for Eye Disease Candidate

Kodiak reports completing patient enrollment in its late-stage study evaluating tarcocimab for diabetic retinopathy.

Zacks last month

KOD
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR").

PR Newswire last month

KOD
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 2 months ago

KOD
Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that senior management will present the Company's pipeline program exploring the treatment of glaucoma at the Glaucoma 360 New Horizons Forum 2025 on Friday, February 7, 2025, in San Francisco, CA.

PR Newswire 2 months ago

KOD
Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing

We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where Kodiak Sciences Inc. (NASDAQ:KOD) stands against the other stocks. One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the […]

Insider Monkey 3 months ago

KOD
Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D., Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025, at 3:00 p.m. Pacific Time.

PR Newswire 3 months ago

KOD
KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Kodiak stock skyrockets 271% in six months on the back of positive updates from the tarcocimab program for treating retinal vascular diseases.

Zacks 3 months ago

KOD

VNDA

CTMX
Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership

Key Insights Significantly high institutional ownership implies Kodiak Sciences' stock price is sensitive to their...

Simply Wall St. 4 months ago

KOD
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.

Zacks 4 months ago

MNPR

ARQT

MSB.AX
KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

Kodiak stock surges as Jefferies upgrades it to a "BUY" rating based on the significant potential of its pipeline candidates for retinal disease indications.

Zacks 4 months ago

KOD

PFE
Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on retinal (eye) diseases. Kodiak’s lead investigational medicine, tarcocimab, is an anti-VEGF antibody biopolymer conjugate under development for high-prevalence retinal vascular diseases. Tarcocimab is currently being studied in two Phase 3 trials, GLOW2 in diabetic retinopathy and DAYBREAK in patients with wet age-related macular degeneration (wet AMD). Both studies are actively enrolling patients. J

Benzinga 4 months ago

KOD
Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks 5 months ago

KOD
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

KOD reports a narrower-than-expected loss for the third quarter of 2024. The company provides updates regarding its pipeline development plans.

Zacks 5 months ago

KOD

PFE

NVS
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended September 30, 2024.

PR Newswire 5 months ago

KOD

Performance Overview

Return	K27.F	S&P 500 (^GSPC)
YTD	-65.72%	-4.67%
1-Year	-9.80%	+8.08%
3-Year	-39.63%	+35.98%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Kodiak Sciences Inc. (K27.F)

Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

April 2025's Promising Penny Stocks

Down -28.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Kodiak Sciences (KOD)

Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

Is Kodiak Sciences Inc. (KOD) The Hot Biotech Stock Under $5?

KOD Completes Enrollment in Phase III Study for Eye Disease Candidate

Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate

Kodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025

Here’s Why Kodiak Sciences Inc. (KOD) Is Skyrocketing

Kodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference

KOD Stock Rallies 271% in 6 Months on Eye Disease Program Updates

Institutional investors have a lot riding on Kodiak Sciences Inc. (NASDAQ:KOD) with 43% ownership

What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

KOD Stock Up as Jefferies Upgrades Rating on Huge Pipeline Potential

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Kodiak Sciences Inc. (KOD) Just Flashed Golden Cross Signal: Do You Buy?

Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus

Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Performance Overview